Company Overview

AbbVie Inc. is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, oncology, aesthetics, neuroscience, and eye care. AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie was formed in 2012 as a corporate spin-off from Abbott Laboratories and became a public company in January 2013.

Market Position and Valuation

As of September 2025, AbbVie has a market capitalization of $382.03 Billion USD, making it the world's 26th most valuable company according to our data. The company trades on the New York Stock Exchange under the ticker symbol ABBV and is included in the S&P 100 index.

Key Product Portfolio

Immunology Franchise - Revenue Drivers

AbbVie's immunology portfolio represents the largest segment of its revenue, anchored by three blockbuster drugs:

- Humira (adalimumab): Generated $9 billion in 2024 revenues (16% of total revenues). Approved to treat autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis. Administered via injection.

- Skyrizi (risankizumab): Achieved $11.718 billion in global net revenues in 2024 (21% of total revenues). Skyrizi is an interleukin-23 (IL-23)-inhibiting monoclonal antibody.

- Rinvoq (upadacitinib): Generated $5.971 billion in global net revenues in 2024 (11% of total revenues). Rinvoq is a small molecule Janus kinase (JAK) inhibitor.

Diversified Therapeutic Areas

AbbVie's product portfolio includes key segments such as Immunology, Oncology, Aesthetics, Neuroscience, and Eye Care. Notable products include Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox Cosmetic, and Juvederm Collection, each contributing significantly to the company's revenue streams.

- Oncology Portfolio: Full-Year Global Net Revenues from the Oncology Portfolio were $6.555 Billion, an increase of 10.8% on a reported basis, or 12.0% on an operational basis. Global Imbruvica Net Revenues were $3.347 Billion; Global Venclexta Net Revenues were $2.583 Billion.

- Other Major Products: Botox ($6.0 billion in 2024 revenues, 11% of total revenues) serves the aesthetics and neuroscience markets.

Financial Performance

2024 Full-Year Results

AbbVie delivered Full-Year Net Revenues of $56.334 Billion, an increase of 3.7% on a reported basis and 4.6% on an operational basis for 2024. Full-Year Diluted EPS was $2.39 on a GAAP Basis (a decrease of 12.1%), and Adjusted Diluted EPS was $10.12 (a decrease of 8.9%).

Q4 2024 Performance

AbbVie delivered Fourth-Quarter Net Revenues of $15.102 Billion, an increase of 5.6% on a reported basis and 6.1% on an operational basis in Q4 2024.

Growth Strategy and Outlook

2025 Guidance and Long-term Projections

AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2025 of $12.12 to $12.32. AbbVie is reaffirming its expectations for a high single-digit compound annual revenue growth rate through 2029. This guidance assumes 2024 as the base year in the compound annual growth rate calculation.

Key Growth Drivers

AbbVie is raising its long-term outlook for Skyrizi and Rinvoq revenues. The company now expects combined Skyrizi and Rinvoq 2027 revenues of more than $31 billion, an increase of approximately $4 billion compared to previous guidance for combined revenues of more than $27 billion in 2027. This guidance assumes Skyrizi revenues of more than $20 billion and Rinvoq revenues of more than $11 billion in 2027.

In 2024, AbbVie reported that Skyrizi and Rinvoq accounted for about $5bn in growth, with the company highlighting how the two products have captured around 50% of the market share in IBD indications such as Crohn's disease and ulcerative colitis.

Strategic Acquisitions and Pipeline Development

Recent Acquisitions

The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, strengthening the company's position in these therapeutic areas.

AbbVie announced that it completed its acquisition of Aliada Therapeutics. The transaction strengthens AbbVie's neuroscience pipeline and R&D capabilities with the addition of a potential best-in-class disease-modifying therapy for Alzheimer's disease (AD), ALIA-1758, and novel blood-brain barrier (BBB)-crossing technology.

Pipeline Developments

AbbVie announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating tavapadon as a flexible-dose monotherapy in early Parkinson's disease (PD). In the study, tavapadon met the primary endpoint, demonstrating a statistically significant improvement from baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined score at week 26.

Business Model and Mission

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, and eye care - and products and services across our Allergan Aesthetics portfolio.

The company operates as a single global business segment with significant market presence in North America, the European Union, Japan, and emerging markets, focusing on maximizing revenue growth from key on-market products while advancing its robust R&D pipeline.